Host-Based Th2 Cell Therapy for Prolongation of Cardiac Allograft Viability

• Shoba Amarnath ,

  Contributed equally to this work with: Shoba Amarnath, Hao Chen

  * E-mail: samarnath@mail.nih.gov

  Affiliation Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Hao Chen ,

  Contributed equally to this work with: Shoba Amarnath, Hao Chen

  Affiliations Critical Care Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, United States of America, Department of Cardiac Surgery, Huadong Hospital, Fudan University, Shanghai, China

  ⨯
• Jason E. Foley,

  Affiliation Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Carliann M. Costanzo,

  Affiliation Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Joel D. Sennesh,

  Affiliation Department of Pathology, Inova Fairfax Hospital, Fairfax, Virginia, United States of America

  ⨯
• Michael A. Solomon,

  Affiliations Critical Care Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, United States of America, Cardiovascular and Pulmonary Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Daniel H. Fowler

  Affiliation Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯